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p < 0.001. The average of referrals was of 70.5 per 100 attended-
patients/year (p < 0.001). 2.5% referrals of the total were made
to the neurological, being patient of greater age, with predomi-
nance of women and displaying the head pain/migraine as main
consultation reason. Visits and episodes explain 43.2%-73.9%
respectively (p < 0.001), the explanatory power of the classiﬁca-
tion’s variability was of 46.3% (p = 0.001) and the referral
20.1%. EI per center were: 0.97 (CI: 0.77–1.18), 0.79 (CI: 0.57–
1.01), 0.88 (CI: 0.62–1.14), 1.29 (CI: 0.94–1.65) and 0.91 (CI:
0.58–1.25), p = 0.023 (family practice) and 0.90 (CI: 0.47–1.33),
0.78 (CI: 0.35–1.21), 0.93 (CI: 0.43–1.44), 1.21 (CI: 0.60–1.82)
and 0.97 (CI: 0.39–1.56), p = 0.031 (pediatrics); respectively.
CONCLUSIONS: Adjusted morbidity by ACG explains an
important part of the referrals variability. A low percentage was
derived to neurology.The study results must be interpreted cau-
tiously even after adjustment by age, gender and morbidity.
Should the results be conﬁrmed it would allow an improvement
in the measurement of referrals for clinical management in the
PCT.
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OBJECTIVES: To determine the budget impact of treatment
patterns for Multiple Sclerosis (MS) based on national guideline.
METHODS: A one-year (October 2006 to September 2007)
retrospective database search was conducted to identify medica-
tion used, costs, patient adherence and provision. The source of
data was the Ministry of Health public available database, called
DATASUS. The study were conduct in four steps: 1) Determine
the medicines codes in the public list; 2) Establish the relation-
ships among drugs and patients usage, based on national guide-
lines; 3) Analyze adherence pattern in the most relevant center in
Brazil, based on medication consumption; and 4) Determine the
budget impact for MS treatment. RESULTS: Medication for MS
was responsible by 13% of high cost medication supplied by
Public Sector in Brazil. During the period of analysis the costs
and number of patients grew more than 100%, in average
60,000 medications per month were supplied and a total 8.294
patients were treated. Patients treated were distributed among
therapeutics alternative as follow: 60.28% to interferon-1a (two
brands), 19.99% to interferon-1b and 19.74 to glatiramer
acetate. Five states out of 27 were responsible by 80% of patients
treated. It was possible to detect the beginning of drug associa-
tion. We found that 26% of patients adhere to disease treatment.
Treatment costs was higher than USD 9 millions per month, the
distribution of costs is similar to the patients distribution due to
fewer combination therapy. CONCLUSIONS: National guide-
lines permits universal access, but the analysis of treatment pat-
terns points to a high concentration of care and this could be an
indicator of health care provision inequalities. Due to the high
costs of treatments and the fast patient growth rates new cost-
efﬁcient alternatives need to be considered as a way to reduce
health system inequalities.
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Depression affects around 40–50% of people with PD [Goetz
2002]. It has been argued that depression in PD can be consid-
ered to be one of the manifestations of the degenerative nature of
the disease on the CNS [Shrag et al 2000]. Any differences in the
aetiology and co-morbidities in depression in PD when compared
to depression in those without PD may result in differences in
antidepressant treatment patterns. Furthermore, certain PD
drugs are metabolised in a way that may lead to their interaction
with certain antidepressants. Awareness of this may impact upon
prescribing decisions both for antidepressant and PD drugs in
those with depression in PD. OBJECTIVES: The objective of this
study is to describe the use of antidepressants in the treatment of
depression in PD patients. METHODS: The study was carried
out using the General Practice Research Database (GPRD). The
GPRD is a database with 9 million patients’ data (3.7 million
being currently active). The search identiﬁed PD patients on
various rates of different antidepressants. The PD patients were
diagnosed with PD from 2002 onwards. RESULTS: The study
identiﬁed 18,481 patients with a diagnosis of PD; 44% of these
also had a diagnosed depression (8,058 of 18,481). Of these PD
patients with depression, 21% had prescriptions for Amitrip-
tyline (1658 of 8058), 19% for Fluoxetine (1549 of 8058),
14% for Citalopram (1125 of 8058), 7% for Venlafaxine
(566 of 8,058) and 5% for Mirtazapine (369 of 8058).
CONCLUSIONS: This study conﬁrms the results of previous
studies that there is a high prevalence of depression in PD patients.
Within a UK context, the study also identiﬁes that a large propor-
tion of these patients receive antidepressant treatments.
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OBJECTIVES: To evaluate the risk of psychiatric disorders and
associated health care expenditures among moderate to severe
psoriasis (PsO) patients using data from a US health care claims
database. METHODS: PsO patients and controls without PsO
were identiﬁed from the PharMetrics health care claims database
using the ICD-9 code of 696.x. Patients with moderate to severe
PsO (N = 7971) had been diagnosed with PsO in both years 2003
and 2004, and had been treated with systemic therapies including
cyclosporine, methotrexate, acitretin, biologics, or phototherapy.
Controls (N = 31884) were matched with PsO cases in a 4:1 ratio
by gender, age, region, and previous time-in-plan. Psychiatric
disorders and anti-psychiatric therapies in year 2004 were com-
pared between groups. RESULTS: PsO cases were equally distrib-
uted between males (50.6%) and females with mean age of 47.2
years. Almost half of the patients received anti-inﬂammatory
drugs, 33.3% received biologic therapies, and 36.7% had photo-
therapy. Compared with controls, patients with moderate to
severe PsO had a statistically signiﬁcantly higher prevalence
(p < 0.01) of anxiety (6.94% vs. 4.37%, OR = 1.63), depression
(9.17% vs. 5.32%, OR = 1.80), bipolar disorder (1.10% vs.
0.51%,OR = 2.16), and delirium (0.25%vs. 0.14%,OR = 1.74).
There was no difference between PsO patients and controls in the
prevalence of dementia or schizophrenia (p > 0.05). Compared
with controls, a greater proportion of PsO patients had been
treated with antidepressants (6.12% vs. 0.90%, OR = 7.18),
anxiolytics (5.03% vs. 0.75%, OR = 7.04), anti-psychotics
(5.90% vs. 0.89%, OR = 6.97) or anti-manics (4.89% vs.
0.74%, OR = 6.93). PsO patients had higher total health care
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